PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29275358-13	2018	Sorafenib-resistant HCC cells showed elevated KRAS expression, and KRAS inhibition resensitised sorafenib-resistant cells to suppression of proliferation and induction of apoptosis.	Sorafenib	0-9	KRAS proto-oncogene, GTPase	Rattus norvegicus	46-50	
29275358-13	2018	Sorafenib-resistant HCC cells showed elevated KRAS expression, and KRAS inhibition resensitised sorafenib-resistant cells to suppression of proliferation and induction of apoptosis.	Sorafenib	96-105	KRAS proto-oncogene, GTPase	Rattus norvegicus	67-71	
29275358-14	2018	CONCLUSIONS: KRAS is dysregulated in HCC by loss of tumour-suppressive microRNA-622, contributing to tumour progression, sorafenib sensitivity and resistance.	Sorafenib	121-130	KRAS proto-oncogene, GTPase	Rattus norvegicus	13-17